Form 4: Design Therapeutics Director Deepa Prasad Acquires Stock Options

Director Deepa Prasad acquired stock options for 19,000 shares of Design Therapeutics, Inc. at an exercise price of $3.82 on June 13, 2024.

Summary

• On June 13, 2024, Deepa Prasad, a director of Design Therapeutics, Inc. (DSGN), acquired stock options for 19,000 shares.
• The exercise price of these options is $3.82.
• The options vest in equal monthly installments over 12 months following June 13, 2024, but will be fully vested by the date of the company's next annual meeting of stockholders.
• The expiration date for these options is June 12, 2034.
• Following the transaction, Deepa Prasad directly owns derivative securities for 19,000 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock option acquisition by a company director. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates